Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Analysis of the results of clinicoimmunological study of the use of autotransfusion of blood treated by ultraviolet irradiation (ABUVI) in infants with acute purulent destructive pneumonia (APDP) revealed that imbalance of cellular and humoral immunity factors was the main factor determining the severity of the disease. ABUVI is an effective measure for correcting the immune response of the child's organism to the bacterial aggression through adequate production of monocytic phagocytes and plasma cells of the blood. It also influences the completeness of humoral immunity and reduction of T-lymphocyte deficiency in the acute phase of the disease. ABUVI raises the efficacy of complex treatment of toxicoseptic forms of APDR, reduces 1.7-fold the terms of treatment, and reduces considerably the mortality rate of this disease in young children.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!